CD22和CD19嵌合抗原受体T细胞（CAR-T）桥接自体造血干细胞移植（auto-HSCT）作为青少年和成人B淋巴细胞白血病（B-ALL）巩固治疗的安全性和有效性 - Suppr

Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL.

作者信息

Qiu Yan, Wan Chao-Ling, Xu Ming-Zhu, Zhou Hai-Xia, Liu Mei-Jing, Gong Wen-Jie, Kang Li-Qing, Sun Ai-Ning, Yu Lei, Wu De-Pei, Qian Chong-Sheng, Xue Sheng-Li

机构信息

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.

Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, 215000, Suzhou, People's Republic of China.

出版信息

Blood Cancer J. 2023 May 3;13(1):66. doi: 10.1038/s41408-023-00837-3.

DOI:10.1038/s41408-023-00837-3

PMID:37137904

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10156719/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07b0/10156719/48c509650206/41408_2023_837_Fig1_HTML.jpg

相似文献

Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL.

Blood Cancer J. 2023 May 3;13(1):66. doi: 10.1038/s41408-023-00837-3.

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.

J Transl Med. 2023 Mar 22;21(1):213. doi: 10.1186/s12967-023-04019-4.

Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.

Leuk Res. 2024 Oct;145:107569. doi: 10.1016/j.leukres.2024.107569. Epub 2024 Aug 22.

Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma.

Cytotherapy. 2023 Feb;25(2):185-191. doi: 10.1016/j.jcyt.2022.10.001. Epub 2022 Oct 22.

Haematology laboratory parameters to assess efficacy of CD19-, CD22-, CD33-, and CD123-directed chimeric antigen receptor T-cell therapy in haematological malignancies.

Int J Lab Hematol. 2022 Aug;44(4):750-758. doi: 10.1111/ijlh.13850. Epub 2022 Apr 13.

Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.

Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13.

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.

Front Immunol. 2022 May 20;13:879983. doi: 10.3389/fimmu.2022.879983. eCollection 2022.

CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study.

Cancer Immunol Res. 2021 Sep;9(9):1061-1070. doi: 10.1158/2326-6066.CIR-20-0675. Epub 2021 Jul 21.

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.

Front Immunol. 2021 Oct 7;12:728962. doi: 10.3389/fimmu.2021.728962. eCollection 2021.

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?

Blood Cancer J. 2023 Apr 24;13(1):60. doi: 10.1038/s41408-023-00819-5.

引用本文的文献

Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia.

J Transl Med. 2025 Apr 3;23(1):391. doi: 10.1186/s12967-025-06399-1.

Advances in hematopoietic stem cell transplantation for autoimmune diseases.

Heliyon. 2024 Oct 11;10(20):e39302. doi: 10.1016/j.heliyon.2024.e39302. eCollection 2024 Oct 30.

本文引用的文献

Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.

Nat Rev Clin Oncol. 2022 May;19(5):342-355. doi: 10.1038/s41571-022-00607-3. Epub 2022 Mar 22.

How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?

Front Immunol. 2020 Dec 15;11:611710. doi: 10.3389/fimmu.2020.611710. eCollection 2020.

Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells.

Bone Marrow Transplant. 2021 Jan;56(1):91-100. doi: 10.1038/s41409-020-0982-6. Epub 2020 Jun 24.

Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients.

Cell Death Dis. 2020 Mar 30;11(3):207. doi: 10.1038/s41419-020-2388-1.

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies.

Blood. 2020 Jan 2;135(1):17-27. doi: 10.1182/blood.2019000017.

Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.

Am J Hematol. 2019 Oct;94(10):1113-1122. doi: 10.1002/ajh.25582. Epub 2019 Aug 2.

Mechanisms of resistance to CAR T cell therapy.

Nat Rev Clin Oncol. 2019 Jun;16(6):372-385. doi: 10.1038/s41571-019-0184-6.

Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2019 Jun;54(6):798-809. doi: 10.1038/s41409-018-0373-4. Epub 2018 Nov 1.

Tumor Antigen Escape from CAR T-cell Therapy.

Cancer Discov. 2018 Oct;8(10):1219-1226. doi: 10.1158/2159-8290.CD-18-0442. Epub 2018 Aug 22.

Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT.

Eur J Cancer. 2018 Jun;96:73-81. doi: 10.1016/j.ejca.2018.03.018. Epub 2018 Apr 18.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献